Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: coronavirus vaccine - Akers Biosciences/Premas Biotech

Drug Profile

Research programme: coronavirus vaccine - Akers Biosciences/Premas Biotech

Latest Information Update: 20 May 2020

At a glance

  • Originator Premas Biotech
  • Class Peptide vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 14 May 2020 Akers Biosciences intends to have discussions with the regulatory authorities of India and USA
  • 14 May 2020 Akers Biosciences plans preclinical trials for COVID-19 infections in summer 2020
  • 24 Mar 2020 Akers Biosciences enters into a licensing agreement with Premas Biotech for the coronavirus Vaccine

Development Overview

Introduction

Coronavirus vaccine is a peptide vaccine being developed by Akers Biosciences under a license from Premas Biotech for the treatment of COVID-2019 infections using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.The vaccine candidate is based on the three COVID-19 proteins namely; spike, envelope and membrane. Early research is underway in the US and India.

D-CryptTm platform has capability to express 30 proteins of similar profile to those in the structure of COVID-19 and the technology platform is highly scalable with a robust process.

Company Agreements

In March 2020, Akers Biosciencesenters into a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™, and partner with Premas to ultimately seek the US FDA approval. Under the terms of the agreement, Akers is acquiring Cystron Biotech LLC for a $US1 million upfront payment, 6 22 756 shares of common stock or common stock equivalents and a royalty on net sales. In addition, Akers shall make additional payments of cash and stock to the sellers of Cystron Biotech LLC upon the achievement of certain milestones, along with a change of control. Akers is also required to make certain cash payments to Premas upon the achievement of additional milestones. [1]

Key Development Milestones

In May 2020, Akers Biosciences successfully completed its vaccine prototype based on the transmission electron microscopic (TEM) images of the recombinant virus like particle (VLP) assembled in yeast. At this time, the company also established manufacturing protocol and commenced large-scale production studies for the vaccine candidate [2] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Peptide vaccines, Viral vaccines, Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7 (Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research India, USA unspecified / unspecified Premas Biotech 24 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Premas Biotech Originator India
Premas Biotech Owner India
Akers Biosciences Licensee USA

Future Events

Expected Date Event Type Description Updated
31 Aug 2020 Trial Update Akers Biosciences plans preclinical trials for COVID-19 infections in summer 2020 [2] 20 May 2020

Development History

Event Date Update Type Comment
14 May 2020 Regulatory Status Akers Biosciences intends to have discussions with the regulatory authorities of India and USA [2] Updated 20 May 2020
14 May 2020 Trial Update Akers Biosciences plans preclinical trials for COVID-19 infections in summer 2020 [2] Updated 20 May 2020
24 Mar 2020 Licensing Status Akers Biosciences enters into a licensing agreement with Premas Biotech for the coronavirus Vaccine [1] Updated 02 Apr 2020
24 Mar 2020 Phase Change Early research in COVID-2019 infections in USA, India (unspecified route) [1] Updated 02 Apr 2020

References

  1. Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech.

    Media Release
  2. Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP.

    Media Release
Back to top